Differential gene expression in pituitary adenomas by oligonucleotide array analysis

European Journal of Endocrinology

Volumn 153, Issue 1, 2005, Pages 143-151

  Morris, Damian G ^a   Muşat, Mädälina ^c   Czirják, Sándor ^b   Hanzély, Zoltán ^b   Lillington, Debra M ^a   Korbonits, Márta ^a   Grossman, Ashley B ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NATIONAL INSTITUTE OF NEUROSURGERY   (Hungary)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; CYCLIN DEPENDENT KINASE INHIBITOR; GLYCOPROTEIN; GROWTH HORMONE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 4 BETA; PROLACTIN; PROTEIN BCL 2; PROTEIN P18; RNA; UNCLASSIFIED DRUG;

ARTICLE; BIOINFORMATICS; CARCINOGENESIS; CELL HYPERPLASIA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; GENE DELETION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN GENOME; HUMAN TISSUE; HYPOPHYSIS ADENOMA; INTRACRANIAL TUMOR; LIVER CELL CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; VALIDATION PROCESS;

EID: 22744436432     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01937     Document Type: Article

References (29)

1. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR & Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989 340 692-696.
2. Pei L & Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Molecular Endocrinology 1997 11 433-441.
3. Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, Swearingen B & Klibanski A. Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. Journal of Clinical Endocrinology and Metabolism 2002 87 1262-1267.
4. Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR & Klibanski A. A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. Journal of Clinical Endocrinology and Metabolism 2003 88 5119-5126.
5. Paez-Pereda M, Giacomini D, Refojo D, Nagashima AC, Hopfner U, Grubler Y, Chervin A, Goldberg V, Goya R, Hentges ST et al. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. PNAS 2003 100 1034-1039.
6. Goidin D, Kappeler L, Perrot J, Epelbaum J & Gourdji D. Differential pituitary gene expression profiles associated- to aging and spontaneous tumors as revealed by rat cDNA expression array. Endocrinology 2000 141 4805-4808.
7. Wood WM, Sarapura VD, Dowding JM, Woodmansee WW, Haakinson DJ, Gordon DF & Ridgway EC. Early gene expression changes preceding thyroid hormone-induced involution of a thyrotrope tumor. Endocrinology 2002 143 347-359.
8. Mohammad HP, Seachrist DD, Quirk CC & Nilson JH. Reexpression of p8 contributes to tumorigenic properties of pituitary cells and appears in a subset of prolactinomas in transgenic mice that hypersecrete luteinizing hormone. Molecular Endocrinology 2004 18 2583-2593.
9. Evans CO, Young AN, Brown MR, Brat DJ, Parks JS, Neish AS & Oyesiku NM. Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. Journal of Clinical Endocrinology and Metabolism 2001 86 3097-3107.
10. Evans CO, Reddy P, Brat DJ, O'Neill EB, Craige B, Stevens VL & Oyesiku NM. Differential expression of folate receptor in pituitary adenomas. Cancer Research 2003 63 4218-4224.
11. Morris DG, Kola B, Borboli N, Kaltsas GA, Gueorguiev M, McNicol AM, Ferrier R, Jones TH, Baldeweg S, Powell M et al. Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 2003 88 6080-6087.
12. Morris DG, Kola B, Grossman AB & Korbonits M. The optimal endogenous control for human pituitary RNA gene expression studies. In Program of the 85th Annual Meeting of The Endocrine Society. 19-22 June 2003, Philadelphia, PA, pp P2-672, Bethesda: The Endocrine Society Press, 2003.
13. Liu XR, Zhou RL, Zhang QY, Zhang Y, Jin YY, Lin M, Rui JA & Ye DX. Structure analysis and expressions of a novel tetratransmembrane protein, lysosoma-associated protein transmembrane 4beta associated with hepatocellular carcinoma. World Journal of Gastroenterology 2004 10 1555-1559.
14. He J, Shao G & Zhou R. [Effects of the novel gene, LAPTM4B, highly expression in hepatocellular carcinoma on cell proliferation and tumorigenesis of NIH3T3 cells]. Bei-jing Da Xue Xue Bao 2003 35 348-352.
15. Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, Su L & Xiong Y. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes & Development 1998 12 2899-2911.
16. McCabe CJ, Khaira JS, Boelaert K, Heaney AP, Tannahill LA, Hussain S, Mitchell R, Olliff J, Sheppard MC, Franklyn JA & Gittoes NJ. Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clinical Endocrinology (Oxford) 2003 58 141-150.
17. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD & Melmed S. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1999 84 761-767.
18. Musat M, Korbonits M, Kola B, Borboli N, Hanson MR, Nanzer AM, Grigson J, Jordan S, Morris DG, Gueorguiev M et al. Enhanced protein kinase B/Akt signaling in pituitary tumours. Endocrine-related Cancer 2005 (in press).
19. Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, Rui JA, Wei X & Ye DX. Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 2003 22 5060-5069.
20. Scheithauer B, Horvath E, Lloyd RV & Kovacs K. Pathology of pituitary adenomas and pituitary hyperplasia. In The Diagnosis and Management of Pituitary Tumors, pp 91-154. Eds K Thapar, K Kovacs, B Scheithauer & RV Lloyd. Humana Press, 2001.
21. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA & Reed JC. Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell 1995 80 279-284.
22. Wang HG, Takayama S, Rapp UR & Reed JC. Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. PNAS 1996 93 7063-7068.
23. Bardelli A, Longati P, Albero D, Goruppi S, Schneider C, Ponzetto C & Comoglio PM. HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death. EMBO Journal 1996 15 6205-6212.
24. Takayama S, Krajewski S, Krajewska M, Kitada S, Zapata JM, Kochel K, Knee D, Scudiero D, Tudor G, Miller GJ et al. Expression and location of Hsp70/Hsc-binding anti-apoptotic protein BAG-1 and its variants in normal tissues and tumor cell lines. Cancer Research 1998 58 3116-3131.
25. Kudoh M, Knee DA, Takayama S & Reed JC. Bag1 proteins regulate growth and survival of ZR-75-71 human breast cancer cells. Cancer Research 2002 62 1904-1909.
26. Woloschak M, Yu A, Xiao J & Post KD. Frequent loss of the P16INK4a gene product in human pituitary tumors. Cancer Research 1996 56 2493-2496.
27. Yu WH, Hui GZ, Wang Q & Wu SR. [Preliminary study of p16 gene expression in pituitary adenomas]. Ai Zheng 2003 22 198-201.
28. Simpson D, Bicknell JE, McNicol AM, Clayton RN & Farrell WE. Hypermethylation of the p16/CDKN2A/MTSI gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas. Genes Chromosomes & Cancer 1999 24 328-336.
29. Lidhar K, Korbonits M, Jordan S, Khalimova Z, Kaltsas G, Lu X, Clayton RN, Jenkins PJ, Monson JP, Besser GM et al. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1999 84 3823-3830.